Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients

Xie, Yandi; Ma, Hui; Feng, Bo; Wei, Lai

doi:10.4103/0366-6999.213969

Cited by 9 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our proteomic approach showed that the F13A concentration was decreased in the blood plasma of patients with B-ALL. This observation has also been documented in whole plasma by ELISA assay in a study by Shi and Wang, in which a decrease of F13A in patients with acute myeloid and lymphoblastic leukemia and in solid tumors was reported [19]. Normal lymphoid cells do not synthesize or contain any F13 subunits, while lymphoid cells in bone marrow samples derived from patients with acute leukemia F13A do.…”

Section: Discussionsupporting

confidence: 66%

A comparative proteomic study of plasma in Colombian childhood acute lymphoblastic leukemia

2019

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Owing to the incorporation of risk-adapted therapy and the arrival of new directed agents, the cure rate and survival of patients with ALL have improved dramatically, get near to 90%. In Latin American countries, the mortality rates of ALL are high, for example in Colombia, during the last decade, ALL has been the most prevalent cancer among children between 0–14 years of age. In the face of this public health problem and coupled with the fact that the knowledge of the proteome of the child population is little, our investigation proposes the study of the plasma proteome of Colombian children diagnosed with B-cell ALL (B-ALL) to determine potential disease markers that could reflect processes altered by the presence of the disease or in response to it. A proteomic study by LC-MS/MS and quantification by label-free methods were performed in search of proteins differentially expressed between healthy children and those diagnosed with B-ALL. We quantified a total of 472 proteins in depleted blood plasma, and 25 of these proteins were differentially expressed (fold change >2, Bonferroni-adjusted P-values <0.05). Plasma Aggrecan core protein, alpha-2-HS-glycoprotein, coagulation factor XIII A chain and gelsolin protein were examined by ELISA assay and compared to shotgun proteomics results. Our data provide new information on the plasma proteome of Colombian children. Additionally, these proteins may also have certain potential as illness markers or as therapeutic targets in subsequent investigations.

show abstract

Section: Discussionsupporting

confidence: 66%

A comparative proteomic study of plasma in Colombian childhood acute lymphoblastic leukemia

2019

View full text Add to dashboard Cite

show abstract

“…It showed significant difference in studies for patients with HBV, HCV, depression, and fever by meta-analysis. Despite this, levels of HBV DNA and HBeAg clearance for CHM formula granules were much lower than for antivirals [50] or interferon [51]. This is a similar finding for patients with HCV RNA and HCV RNA clearance levels for CHM formula granules were much lower than for antivirals [52].…”

Section: Discussionmentioning

confidence: 78%

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Han

Lai

Li³

et al. 2019

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To summarize the characteristics and the outcomes of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Granules manufactured by China Resources Sanjiu Pharmaceutical Co., Ltd. Methods. Databases including China National Knowledge Infrastructure, VIP, Wanfang, PubMed, Cochrane Library, and clinicaltrials.gov were searched in March 2018 for relevant randomized controlled trials (RCTs). Two reviewers independently screened for and selected studies, extracted data, and checked data extraction. Methodological quality was evaluated using the Cochrane Risk of Bias tool. For the outcome, the characteristics of the study, the cure rate, the effectiveness rate, and advert events were described with a method of bibliometrics. Also, we performed meta-analysis only if there were ≥2 studies treated by the same intervention and evaluated by the same outcome. Results. A total of 40 placebo-controlled RCTs treated for 17 diseases were included in our analysis involving 4,632 patients. 16 of 19 studies treated by CHM granules only showed positive result in patients with HBV, HCV, fever, depression, nonalcoholic fatty liver disease, AIDS, and asthma while negative result was shown in patients with migraine. 17 of 21 studies treated by combination therapy against conventional therapy showed positive result in patients with HBV, herpes simplex keratitis, COPD, liver cirrhotic ascites, Parkinson’s disease, and diabetic peripheral neuropathy while negative result was shown in patients with myasthenia gravis, angina pectoris, and depression. The pooled result cannot demonstrate that the notifying kidney formula granules had the superior effect with placebo on the clearance of serum HBV DNA and HBeAg in HBV carriers with a RR (and the 95% CI) of 2.97 [0.74,11.91] and 1.99 [0.93,4.29], respectively. But, the CHM granules can reduce within-group HBV DNA levels by more than 2 lgIU/ml; the RR (and 95% CI) was 4.64 [2.89,7.45]. Qizhu granules had a significant effect on clearance of HCV RNA with a RR (and 95% CI) of 6.26 [2.16,18.16]. And, the heat-clearing and detoxifying formula granules were superior to placebo in resolution of cold symptom among patients with fever with a RR and 95% CI of 2.58 [1.40,4.74]. Based on the conventional therapy, the pooled result demonstrated that the Regulating liver formula granules were superior to placebo on the clearance of serum HBeAg in chronic hepatitis B patients with a RR (and the 95% CI) of 1.73 [1.30,2.31]. The EeChen decoction granules were superior to placebo in COPD patients with a RR (and the 95% CI) of 1.13 [1.06,1.22]. 28 of the 40 studies reported adverse events. There were 51 adverse events in CHM formula granules group or combination group (n=2,483) and 26 in control group (n=2,122) totally. Most of the adverse symptoms spontaneously resolved after completing the courses of treatment and the other adverse symptoms improved after symptomatic treatment. Conclusion. 16 of 19 studies treated by CHM granules only showed positive result in 7 diseases and negative result in 1 disease. 17 of 21 studies treated by combination therapy against conventional therapy showed positive result in 6 diseases and negative result in 3 diseases. However, both the absolute and relative effectiveness of CHM formula granules compared with placebo need to be considered clinically.

show abstract

“…To our knowledge, HBeAg‐positive patients with high baseline serum HBV DNA levels usually indicated high risk of poor response to NAs therapy 13‐19 . In a previous study, about 26.2% of patients treated with ETV resulted in PVR, and the baseline serum HBV DNA level was an independent risk factor for PVR 20 . Thus, high baseline HBV DNA level seemed to be one of the important factors related with PVR.…”

Section: Discussionmentioning

confidence: 92%

Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment

Tao

Zhang

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Not all treatment‐naïve patients receiving entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy can achieve complete virological response, and many factors may be related with the outcome of partial virological response. This study aimed to determine whether the manner of drug administration affects the antiviral efficacy of ETV/TDF monotherapy. All eligible patients were divided into complete or partial response cohorts based on their virological response following 24‐week therapy. Factors related with partial response were evaluated. Patients with partial response were further grouped depending on whether they later adjusted the manner of drug administration, and the antiviral efficacy was compared between the two groups during prolonged treatment. A total of 518 patients were enrolled. Suboptimal drug administration (OR 77.511, P = .000), positive‐HBeAg (OR 3.191, P = .000) and ETV treatment (OR 2.537, P = .001) were identified as independent risk factors for partial response. Among patients with partial response, 213 were in the adjusted group and 76 were in the unadjusted group. The percentages of patients with undetectable serum HBV DNA (78.9% vs 31.6%, P < .001) and with normal alanine aminotransferase (ALT) (88.7% vs 68.4%, P < .001) were both higher in the adjusted group than that in unadjusted group following a further 6‐month therapy. In conclusion, the manner of drug administration is an important factor influencing the efficacy of ETV/TDF therapy, and optimal drug administration manner can help to increase antiviral efficacy and rescue patients with partial response.

show abstract

Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients

Cited by 9 publications

References 29 publications

A comparative proteomic study of plasma in Colombian childhood acute lymphoblastic leukemia

A comparative proteomic study of plasma in Colombian childhood acute lymphoblastic leukemia

An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment

Contact Info

Product

Resources

About